Introduction to Baike
Changchun Bio-Pharmaceutical Co., Ltd. (hereinafter referred to as “ Company ” or “ Baike Bio ” ) Founded in 2004 Year, 20 For many years, the company has been dedicated to the biopharmaceutical sector and is a high-tech biopharmaceutical enterprise primarily engaged in the research, development, production, and sales of human vaccines. Its core product portfolio focuses on three major vaccines: live attenuated varicella vaccine, lyophilized live attenuated influenza vaccine for nasal spray, and live attenuated shingles vaccine. The company has... 2021 year 6 The company was listed on the Shanghai Stock Exchange. 2024 Annual main business revenue 12.29 100 million yuan, net profit 2.32 100 million yuan.
The company has established 3 One center: the National Enterprise Technology Center, the Jilin Provincial Modern Vaccine Engineering Research Center, and the Jilin Provincial Biocan Vaccine Science and Technology Innovation Center; 2 Two laboratories: the National Engineering Laboratory for AIDS Vaccines and the Joint Laboratory (Baike). + Institute of Pathogen Biology, Chinese Academy of Medical Sciences); 1 It hosts a national postdoctoral research workstation; is recognized as a National High-Tech Enterprise, a key enterprise under the Ministry of Industry and Information Technology’s priority monitoring and coordination system for economic operations, a Jilin Province Manufacturing Single-Champion Enterprise, and the leading entity of the Jilin Province Biopharmaceutical Industry Science and Technology Innovation Alliance; and has received such honors as the China Patent Excellence Award, the Third Prize of the Jilin Province Science and Technology Progress Award, and the Jilin Province Changbai Mountain Pharmaceutical Innovation Award (Award for Technology Transfer).
The company’s flagship products include the live attenuated varicella vaccine, the lyophilized intranasal live attenuated influenza vaccine, and the live attenuated shingles vaccine, with a primary focus on the R&D, manufacturing, and sales of human vaccines in the biopharmaceutical sector. The company’s live attenuated varicella vaccine is the first in China to be formulated without animal-derived gelatin and boasts a shelf life of 36 The one-month-old varicella vaccine boasts the best stability among similar products and has maintained a nationwide leading market share for many years; the lyophilized live attenuated influenza vaccine administered via nasal spray has been included in the World Health Organization’s ( WHO ) Global Influenza Vaccine Action Plan Project (GAP) , is the only domestically produced live attenuated influenza vaccine administered via intranasal spray; the live attenuated shingles vaccine is China’s first vaccine for the prevention of shingles, thereby achieving domestic substitution for shingles vaccines. Currently, the products are available nationwide, excluding Hong Kong, Macao, and Taiwan. 31 It is sold in provinces, autonomous regions, and municipalities directly under the central government, as well as exported to countries such as India and Pakistan.
The company is based on “ Market-driven, technology-led, and policy-incentivized ” To drive innovation, the company seamlessly integrates market demand, technological development trends, and its own production, operations, and strategic planning. It has established industry–university–research collaborations with leading institutions such as Jilin University, Dalian University of Technology, the Institute of Pathogen Biology of the Chinese Academy of Medical Sciences, and the Institute of Biophysics of the Chinese Academy of Sciences, fostering deep integration between cutting-edge technologies and industrialization platforms and thereby providing strong impetus for the development of the regional biopharmaceutical industry chain.